Background

Oxidative phosphorylation (OXPHOS) is an important process which occurs within the mitochondria of cells. This cascade consists of over 90 proteins which work together to link the TCA cycle to the production of ATP. Tumor cells rely on this process just as normal cells do for bioenergetics and biomass production. Inhibitors of OXPHOS currently exist and are used in the treatment of cancer as well as other mitochondria function disorders including inflammatory diseases, autoimmune disease, cardiovascular disease, diabetes, and neurodegenerative disease. However, current therapeutics often fall short of effectively treating these diseases.